Abcam, ab168381, Anti-Alpha-synuclein (phospho S129) antibody [MJF-R13 (8-8)]

Size: 20µL / 100µL / 1mL
Anti-Alpha-synuclein (phospho S129) antibody [MJF-R13 (8-8)] (ab168381) is a rabbit monoclonal antibody detecting Alpha-synuclein in Western Blot, IHC-P . Suitable for Human . - Biophysical QC for unrivalled batch-batch consistency - Over 40 publications
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:MJF-R13 (8-8),
Isotype:IgG,
Carrier free:No,
Reacts with:Human,
Applications:WB, IHC-PSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.,
Specificity:This antibody only detects alpha Synuclein phosphorylated on Ser129.

Product details:
Anti-Alpha-synuclein (phospho S129) antibody [MJF-R13 (8-8)] (ab168381) was developed by Abcam using patented rabbit monoclonal antibody technology and is validated for use in IHC-P, WB in human samples.
Anti-Alpha-synuclein (phospho S129) antibody [MJF-R13 (8-8)] (ab168381) has been cited over 40 times in peer reviewed journals and is trusted by the scientific community.
Abcam's high quality manufacturing and validation processes ensure Anti-Alpha-synuclein (phospho S129) antibody (Anti-pS129 alpha-synuclein antibody) [MJF-R13 (8-8)] (ab168381) has high sensitivity and specificity alongside high lot-to-lot consistency and reproducibility.
Anti-Alpha-synuclein (phospho S129) antibody [MJF-R13 (8-8)] (ab168381) has 4 independent reviews from customers.
Anti-Alpha-synuclein (phospho S129) antibody [MJF-R13 (8-8)] (ab168381) specifically detects Alpha-synuclein Phospho-S129 (UniProt ID: P37840; Molecular weight: 14kDa) and is sold in 100 µL and 1 mL selling sizes.
Anti-Alpha-synuclein (phospho S129) antibody [MJF-R13 (8-8)] (ab168381) was developed by Abcam in partnership with the Michael J. Fox Foundation for Parkinson's Research.
Alpha-synuclein phosphorylated at serine 129 (pS129; SNCA/NACP) is a key pathological marker in neurodegenerative diseases such as Parkinson's disease. This phosphorylation event is associated with the abnormal aggregation of alpha-synuclein into Lewy bodies, which are indicative of disease. Studies have shown that pS129 not only promotes the aggregation of alpha-synuclein but also increases its neurotoxicity, contributing to neuronal death and disease progression
Alpha-synuclein was the first gene to be linked to Parkinson's disease (PD) and remains the most promising link to PD pathogenesis, where there is genetic evidence that it may play a causal role. In the brain, alpha-synuclein is concentrated in presynaptic nerve terminals. The deposition of the abundant presynaptic brain protein alpha-synuclein as fibrillary aggregates in neurons or glial cells is a hallmark lesion in a subset of neurodegenerative disorders. These disorders include Parkinson's disease (PD), dementia with Lewy bodies (DLB) and multiple system atrophy, collectively referred to as synucleinopathies. Parkinson's disease (PD) is a common neurodegenerative disorder characterized by the progressive accumulation in selected neurons of protein inclusions containing alpha-synuclein and ubiquitin.
Recent studies also indicate that alpha-synuclein undergoes post-translational modification. Though the role of many of these modifications is still under investigation, phosphorylation at Serine 129 may affect alpha-synuclein aggregations and may also serve as marker of disease pathogenesis. With the advent of this phospho-specific Serine 129 antibody, The Michael J. Fox Foundation hopes to ensure that the putative role of this modification can be further examined by all researchers.
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Collaborations
This antibody was developed with support from The Michael J. Fox Foundation.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-Preservative: 0.01% Sodium azideConstituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA, Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Alpha-synuclein often referred to by alternate names such as SNCA is a protein of around 14 kDa mass. It mainly expresses in the brain particularly in presynaptic nerve terminals. This protein functions mechanically by stabilizing synaptic vesicles and maintaining synaptic function. It exists both in soluble monomer forms and as aggregates in protein filaments. Antibodies like 4D6 and EP1536Y target monomer forms of protein for more detailed studies.
Biological function summary
The alpha-synuclein protein plays critical roles in neuronal activity. It contributes to neurotransmitter release regulation by acting in the formation and plasticity of the presynaptic neuronal network. Alpha-synuclein doesn't usually form parts of large protein complexes but it may associate transiently with membranes and vesicular structures. The protein's monomer form has also been observed in alpha lines and related neuronal processes operating alongside various cellular functions.
Pathways
Synaptic vesicle trafficking and dopamine neurotransmitter release are significant areas involving the alpha-synuclein protein. In these pathways alpha-synuclein interacts with other proteins like synaptophysin and protein monomer monomerizations are intrinsic to these processes. Altered function or aggregation of alpha-synuclein disrupts these pathways influencing broader neurological functions.
Alterations or accumulations of alpha-synuclein are strongly linked to Parkinson's disease and Lewy body dementia. In these conditions alpha-synuclein forms abnormal protein filaments known as Lewy bodies within neurons. These formations disrupt cellular processes and neuron health. Synucleinopathies such as these show connections with proteins like parkin and DJ-1 which also have key roles in these neurodegenerative diseases.